Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Lung08: datopotamab deruxtecan plus pembrolizumab versus pembrolizumab in first-line PD-L1-high advanced non-small cell lung cancer
2023-507933-12-00Phase 3Authorised
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 28
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Datopotamab deruxtecan + pembrolizumab with Pembrolizumab alone (2 arms). Primary endpoints: Progression-free survival and Overall survival. Planned start Aug 2022; status: authorised.
02
Drugs
pembrolizumabdatopotamab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-507933-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507933-12-00.